Side-by-side · Research reference
P21vsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BFDA-ApprovedHUMAN-REVIEWED13/41 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
P21
PT-141
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
P21
PT-141
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
Not specified
PRN; reassess if no benefit after 8 doses
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Standard dose
—
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
—
PRN, max 8 doses / month
Lower / starter dose
—
1 mg (off-label)
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
—
≥45 min before sexual activity
04Side Effects & Safety
Parameter
P21
PT-141
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Flushing
—
Common, transient
Injection site reaction
—
Erythema, mild pain
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Pregnancy / OB
—
Contraindicated
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
P21
- ·Use in humans not validated
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
P21
PT-141
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
SQ — abdomen or thigh.
3. Timing
—
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
—
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
—
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.